Cargando…

Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma

PURPOSE: The goal of the current study was to identify potential prognostic biomarkers of rhabdomyosarcoma (RMS). MATERIALS AND METHODS: We screened chip sequencing datasets of RMS through the gene expression omnibus (GEO) database. A total of 74 RMS patient tissues and 39 normal muscle cell tissues...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Suying, Sun, Chengtao, Chen, Huimou, Zhang, Chao, Li, Wei, Wu, Liuhong, Zhu, Jia, Sun, Feifei, Huang, Junting, Wang, Juan, Zhen, Zijun, Cai, Ruiqing, Sun, Xiaofei, Zhang, Yizhuo, Zhang, Xing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705535/ https://www.ncbi.nlm.nih.gov/pubmed/33273853 http://dx.doi.org/10.2147/CMAR.S265779

Ejemplares similares

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Identification of prognostic immune-related genes in rhabdoid tumor of kidney based on TARGET database analysis
por: Chen, Huimou, et al.
Publicado: (2021)

Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
por: Lu, Suying, et al.
Publicado: (2021)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2022)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
por: Chen, Binbin, et al.
Publicado: (2022)

CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis
por: Li, Qianru, et al.
Publicado: (2019)

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children
por: Zhu, Jia, et al.
Publicado: (2021)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Multimodal Treatment of Children With Sacrococcygeal Yolk Sac Tumor: Retrospective Analysis of Clinicopathology Characteristics and Relapse-free Survival
por: Zhu, Jia, et al.
Publicado: (2021)

Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities
por: Zeng, Chenggong, et al.
Publicado: (2023)

Bioinformatics prediction and experimental verification identify MAD2L1 and CCNB2 as diagnostic biomarkers of rhabdomyosarcoma
por: Xia, Tian, et al.
Publicado: (2021)

ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma
por: Li, Mengzhen, et al.
Publicado: (2021)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies
por: Sun, Xiaofei, et al.
Publicado: (2021)

Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients
por: Lan, Yingxia, et al.
Publicado: (2023)

CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China
por: Huang, Junting, et al.
Publicado: (2020)

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
por: Sun, Chengtao, et al.
Publicado: (2020)

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China
por: Hong, Ye, et al.
Publicado: (2023)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Role of post-chemotherapy radiation in the management of children and adolescents with primary advanced malignant mediastinal germ cell tumors
por: Huang, Junting, et al.
Publicado: (2017)

Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma
por: Shi, Yuan-Xiang, et al.
Publicado: (2016)

Long-Term Outcomes of Nasopharyngeal Carcinoma in 148 Children and Adolescents
por: Lu, Suying, et al.
Publicado: (2016)

Identification of CDK1 as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis
por: Qin, Si, et al.
Publicado: (2021)

MAD1-dependent recruitment of CDK1-CCNB1 to kinetochores promotes spindle checkpoint signaling
por: Alfonso-Pérez, Tatiana, et al.
Publicado: (2019)

Mad3 modulates the G(1) Cdk and acts as a timer in the Start network
por: Pérez, Alexis P., et al.
Publicado: (2022)

MYBPC2 and MYL1 as Significant Gene Markers for Rhabdomyosarcoma
por: Chen, Zihang, et al.
Publicado: (2021)

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
por: Park, Silvia, et al.
Publicado: (2014)

Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis
por: Chen, Qian, et al.
Publicado: (2022)

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis
por: Huang, Junting, et al.
Publicado: (2023)

DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma
por: Virgone, Calogero, et al.
Publicado: (2015)

Cyclin B1-Cdk1 facilitates MAD1 release from the nuclear pore to ensure a robust spindle checkpoint
por: Jackman, Mark, et al.
Publicado: (2020)

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2019)

Mad Poets. No. 1
Publicado: (1878)

Mad Actors. No. 1
Publicado: (1882)

Cannot write session to /tmp/vufind_sessions/sess_871kljkrdk87dlb4dr2s4hpgfm